The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors ...

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide GLP-1 medication. In this article, we delve into Hers ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce inflammation and improve heart health. With such advantages, the demand ...